News

Novo Nordisk has announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, for production of the company’s current and future product portfolio within serious chronic diseases.

The investment is intended to create additional capacity across its entire value chain from the manufacturing of active pharmaceutical ingredients (API) to packaging, although the majority of the investment will focus on API capacity.

The new API facility will have a footprint of 170,000m2 and is intended to be ‘designed as a multi-product facility with flexibility to accommodate future processes and displaying state-ofthe-art technolog y and working environment,’ according to the company’s press release.

Henrik Wulff, executive vice president, Product Supply, Quality and IT, Novo Nordisk, commented: "The significant investment announced today confirms the importance of utilising our existing sites, including in Denmark, as cornerstones for not only the growth we see but also to expand as fast as possible by utilising all the infrastructure, knowledge and competences we already have. Our continued investment in global capacity demonstrates the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases.”

It is hoped that the construction projects will be finalised between 2025 and 2029, as well as being expected to create 800 new jobs once completed.